Search research articles
Contact Us
Filters
Showing results (71-80 of 80) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 80 results.
Blood
|
October 26, 2000
High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity
C Seidel, M Børset, O Hjertner, et al.
Infection and Immunity
|
November 18, 2000
Involvement of CD14 and beta2-integrins in activating cells with soluble and particulate lipopolysaccharides and mannuronic acid polymers
T H Flo, L Ryan, L Kilaas, et al.
The Journal of Experimental Medicine
|
December 1, 1992
Soluble CD14 participates in the response of cells to lipopolysaccharide
E A Frey, D S Miller, T G Jahr, et al.
Blood
|
September 25, 2001
Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease
C Seidel, Ø Hjertner, N Abildgaard, et al.
Leukemia
|
September 24, 2011
Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC
T Holien, T K Våtsveen, H Hella, et al.
Blood Cancer Journal
|
July 16, 2016
Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells
K K Starheim, T Holien, K Misund, et al.
The Journal of Urology
|
February 25, 1998
Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis
A M Jackson, A V Ivshina, O Senko, et al.
Blood Cancer Journal
|
March 25, 2014
Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin
O E Olsen, K F Wader, K Misund, et al.
Oncogene
|
April 12, 2011
Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells
U-M Fagerli, K Ullrich, T Stühmer, et al.
Blood Cancer Journal
|
March 21, 2015
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis
E H Rustad, H Y Dai, H Hov, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 80) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 80 results.
Blood
|
October 26, 2000
High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity
C Seidel, M Børset, O Hjertner, et al.
Infection and Immunity
|
November 18, 2000
Involvement of CD14 and beta2-integrins in activating cells with soluble and particulate lipopolysaccharides and mannuronic acid polymers
T H Flo, L Ryan, L Kilaas, et al.
The Journal of Experimental Medicine
|
December 1, 1992
Soluble CD14 participates in the response of cells to lipopolysaccharide
E A Frey, D S Miller, T G Jahr, et al.
Blood
|
September 25, 2001
Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease
C Seidel, Ø Hjertner, N Abildgaard, et al.
Leukemia
|
September 24, 2011
Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC
T Holien, T K Våtsveen, H Hella, et al.
Blood Cancer Journal
|
July 16, 2016
Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells
K K Starheim, T Holien, K Misund, et al.
The Journal of Urology
|
February 25, 1998
Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis
A M Jackson, A V Ivshina, O Senko, et al.
Blood Cancer Journal
|
March 25, 2014
Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin
O E Olsen, K F Wader, K Misund, et al.
Oncogene
|
April 12, 2011
Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells
U-M Fagerli, K Ullrich, T Stühmer, et al.
Blood Cancer Journal
|
March 21, 2015
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis
E H Rustad, H Y Dai, H Hov, et al.
Page
of 8